

Molecular Stratification of Clear Cell Renal Cell Carcinoma Reveals Distinct Subtypes and Survival Patterns

Genes and Cancer

1, 152-163

DOI: [10.1177/1947601909359929](https://doi.org/10.1177/1947601909359929)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Emerging molecular classification in renal cell carcinoma: implications for drug development. Targeted Oncology, 2010, 5, 75-84.	1.7	7
2	Renal Cell Carcinoma: Where Will the State-of-the-Art Lead Us?. Current Oncology Reports, 2010, 12, 193-201.	1.8	17
3	Robust multi-tissue gene panel for cancer detection. BMC Cancer, 2010, 10, 319.	1.1	11
4	Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Systems Biology, 2010, 4, 51.	3.0	223
5	Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules. Expert Opinion on Biological Therapy, 2010, 10, 1517-1520.	1.4	2
6	Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma. Molecular Oncology, 2011, 5, 465-474.	2.1	16
7	What can molecular pathology contribute to the management of renal cell carcinoma?. Nature Reviews Urology, 2011, 8, 255-265.	1.9	66
8	Clinical genomics of renal epithelial tumors. Cancer Genetics, 2011, 204, 285-297.	0.2	80
9	Pazopanib in the treatment of renal cell carcinoma. Clinical Investigation, 2011, 1, 75-85.	0.0	3
10	NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-29.	2.3	48
11	Basic Research in Kidney Cancer. European Urology, 2011, 60, 622-633.	0.9	55
12	Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncology, 2011, 7, 1247-1253.	1.1	28
13	Predictors of Response to Targeted Therapy in Renal Cell Carcinoma. Archives of Pathology and Laboratory Medicine, 2012, 136, 490-495.	1.2	17
14	Predictive models for the practical management of renal cell carcinoma. Nature Reviews Urology, 2012, 9, 73-84.	1.9	13
15	Incidental Detection of Renal Cell Carcinoma is an Independent Prognostic Marker: Results of a Long-Term, Whole Population Study. Journal of Urology, 2012, 187, 48-53.	0.2	58
16	Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA Journal, 2012, 3, 1.	3.3	18
17	Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. British Journal of Cancer, 2012, 107, 1009-1016.	2.9	31
18	Biomarkers for Renal Cell Carcinoma. , 2012, , 47-65.		1

#	ARTICLE	IF	CITATIONS
19	Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. <i>BMC Cancer</i> , 2012, 12, 310.	1.1	25
20	Renal cancer biomarkers: the promise of personalized care. <i>BMC Medicine</i> , 2012, 10, 112.	2.3	61
21	Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma. <i>Human Pathology</i> , 2012, 43, 1982-1990.	1.1	35
22	The Use of Automated Quantitative Analysis to Evaluate Epithelial-to-Mesenchymal Transition Associated Proteins in Clear Cell Renal Cell Carcinoma. <i>PLoS ONE</i> , 2012, 7, e31557.	1.1	22
23	Full-Length Enrich c-DNA Libraries-Clear Cell-Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2012, 2012, 1-15.	0.6	3
24	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. <i>New England Journal of Medicine</i> , 2012, 366, 883-892.	13.9	6,769
25	State of the Science: An Update on Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2012, 10, 859-880.	1.5	142
26	A prognostic gene expression signature in infratentorial ependymoma. <i>Acta Neuropathologica</i> , 2012, 123, 727-738.	3.9	148
27	Meta-analysis of Clear Cell Renal Cell Carcinoma Gene Expression Defines a Variant Subgroup and Identifies Gender Influences on Tumor Biology. <i>European Urology</i> , 2012, 61, 258-268.	0.9	88
28	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. <i>European Urology</i> , 2012, 61, 307-316.	0.9	52
29	Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. <i>BJU International</i> , 2012, 109, 1864-1870.	1.3	56
30	Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications. <i>Cancer Letters</i> , 2013, 341, 111-126.	3.2	101
31	Three Approaches to Data Analysis. <i>Intelligent Systems Reference Library</i> , 2013, , .	1.0	29
32	Dissecting cancer heterogeneity – An unsupervised classification approach. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 2574-2579.	1.2	28
33	Current and future systemic treatments for renal cell carcinoma. <i>Seminars in Cancer Biology</i> , 2013, 23, 38-45.	4.3	100
34	Vasohibin-1 is a new predictor of disease-free survival in operated patients with renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2013, 66, 613-619.	1.0	24
35	Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. <i>Lancet Oncology</i> , The, 2013, 14, 159-167.	5.1	383
36	Prognosis of renal-cell carcinoma: recognising host genetics. <i>Lancet Oncology</i> , The, 2013, 14, 9-10.	5.1	1

#	ARTICLE	IF	CITATIONS
37	Integrated molecular analysis of clear-cell renal cell carcinoma. <i>Nature Genetics</i> , 2013, 45, 860-867.	9.4	955
38	Optimal Management of Metastatic Renal Cell Carcinoma: Current Status. <i>Drugs</i> , 2013, 73, 427-438.	4.9	95
39	Comprehensive molecular characterization of clear cell renal cell carcinoma. <i>Nature</i> , 2013, 499, 43-49.	13.7	2,839
40	Biomarkers for Anti-Angiogenic Therapy in Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 9338-9364.	1.8	58
41	Integrative Genome-Wide Gene Expression Profiling of Clear Cell Renal Cell Carcinoma in Czech Republic and in the United States. <i>PLoS ONE</i> , 2013, 8, e57886.	1.1	99
42	Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 279-288.	1.1	16
43	Polybrominated (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma. <i>BJU International</i> , 2014, 113, E157-63.	1.3	54
44	Tumor Subtype-Specific Cancer-Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers. <i>Cancer Immunology Research</i> , 2014, 2, 371-379.	1.6	90
45	Whole-Transcriptome profiling of formalin-fixed, paraffin-embedded renal cell carcinoma by RNA-seq. <i>BMC Genomics</i> , 2014, 15, 1087.	1.2	60
46	Classification models for clear cell renal carcinoma stage progression, based on tumor RNAseq expression trained supervised machine learning algorithms. <i>BMC Proceedings</i> , 2014, 8, S2.	1.8	47
47	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. <i>European Urology</i> , 2014, 66, 936-948.	0.9	141
48	The Immune Microenvironment: A Major Player in Human Cancers. <i>International Archives of Allergy and Immunology</i> , 2014, 164, 13-26.	0.9	63
49	Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future. <i>Oncologist</i> , 2014, 19, 851-859.	1.9	57
50	A study exploring critical pathways in clear cell renal cell carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2014, 7, 121-130.	0.8	12
51	Loss of CDC14B Expression in Clear Cell Renal Cell Carcinoma. <i>American Journal of Clinical Pathology</i> , 2014, 141, 551-558.	0.4	11
52	ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2014, 66, 77-84.	0.9	234
53	Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. <i>International Journal of Cancer</i> , 2014, 134, 2322-2329.	2.3	40
54	Nucleic acid-based tissue biomarkers of urologic malignancies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 173-199.	2.7	33

#	ARTICLE	IF	CITATIONS
55	How to get the most from microarray data: advice from reverse genomics. <i>BMC Genomics</i> , 2014, 15, 223.	1.2	12
56	Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1929-1941.	1.9	57
57	Identification of genes and pathways involved in kidney renal clear cell carcinoma. <i>BMC Bioinformatics</i> , 2014, 15, S2.	1.2	45
58	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). <i>EBioMedicine</i> , 2015, 2, 1814-1820.	2.7	13
62	A Five-Gene Signature Predicts Prognosis in Patients with Kidney Renal Clear Cell Carcinoma. <i>Computational and Mathematical Methods in Medicine</i> , 2015, 2015, 1-7.	0.7	25
63	Three Dimensional Culture of Human Renal Cell Carcinoma Organoids. <i>PLoS ONE</i> , 2015, 10, e0136758.	1.1	37
64	Distinct transcriptional responses elicited by unfolded nuclear or cytoplasmic protein in mammalian cells. <i>ELife</i> , 2015, 4, .	2.8	20
65	Molecular Determinants of Metastasis in Renal Cell Cancer: Tracking Down the Real Killer. <i>Journal of Urology</i> , 2015, 194, 278-279.	0.2	1
66	A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. <i>Lancet Oncology</i> , The, 2015, 16, 676-685.	5.1	229
67	Prognostication in localised renal cell carcinoma. <i>Lancet Oncology</i> , The, 2015, 16, 603-604.	5.1	10
68	Personalized Medicine in Kidney Cancer: Learning How to Walk Before We Run. <i>European Urology</i> , 2015, 68, 1021-1022.	0.9	4
69	Microarrays and Renal Cell Cancer Biomarkers. <i>Biomarkers in Disease</i> , 2015, , 273-301.	0.0	0
70	Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. <i>Modern Pathology</i> , 2015, 28, 1225-1235.	2.9	23
71	Prognostic Gene Signature Identification Using Causal Structure Learning: Applications in Kidney Cancer. <i>Cancer Informatics</i> , 2015, 14s1, CIN.S14873.	0.9	6
73	Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. <i>European Urology</i> , 2015, 68, 1016-1020.	0.9	55
74	Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 631-646.	1.5	15
75	Tumour and patient factors in renal cell carcinoma—towards personalized therapy. <i>Nature Reviews Urology</i> , 2015, 12, 253-262.	1.9	22
76	VHL and HIF in Clear Cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications. , 2015, , 57-110.		0

#	ARTICLE	IF	CITATIONS
77	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. <i>Clinical Cancer Research</i> , 2015, 21, 1329-1339.	3.2	250
78	Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma. <i>Molecular Cancer</i> , 2015, 14, 141.	7.9	20
79	The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. <i>Radiology</i> , 2015, 277, 114-123.	3.6	61
80	Relapse models for clear cell renal carcinoma. <i>Lancet Oncology</i> , The, 2015, 16, e376-e378.	5.1	3
81	Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications. <i>European Urology</i> , 2015, 67, 729-737.	0.9	100
82	Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis ¹ These authors contributed equally to the writing of this article.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 68.e17-68.e23.	0.8	10
83	Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 82671-82685.	0.8	12
84	Cancer subtypes classification using long non-coding RNA. <i>Oncotarget</i> , 2016, 7, 54082-54093.	0.8	38
85	Intratumor heterogeneity in clear cell renal cell carcinoma: a review for the practicing pathologist. <i>Apmis</i> , 2016, 124, 153-159.	0.9	24
86	Study design requirements for RNA sequencing-based breast cancer diagnostics. <i>Scientific Reports</i> , 2016, 6, 20200.	1.6	2
87	Intrinsic Genomic Differences Between African American and White Patients With Clear Cell Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 664.	3.4	54
88	Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related Death. <i>European Urology Focus</i> , 2016, 2, 608-615.	1.6	7
89	Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor- Directed Therapies Fail. <i>Journal of Oncology Practice</i> , 2016, 12, 412-420.	2.5	11
90	Target molecule expression profiles in metastatic renal cell carcinoma: Development of individual targeted therapy. <i>Tissue Engineering and Regenerative Medicine</i> , 2016, 13, 416-427.	1.6	4
91	Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1326-1332.	1.1	22
92	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016, 17, 231.	3.8	746
93	Molecular profiling of renal cell carcinoma. <i>Current Opinion in Urology</i> , 2016, 26, 383-387.	0.9	22
94	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. <i>Cell Reports</i> , 2016, 14, 2476-2489.	2.9	298

#	ARTICLE	IF	CITATIONS
95	Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. <i>Molecular Cancer Research</i> , 2016, 14, 589-598.	1.5	29
96	High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 238.e19-238.e26.	0.8	12
97	Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. <i>Clinical Cancer Research</i> , 2016, 22, 2950-2959.	3.2	21
98	ROTS: reproducible RNA-seq biomarker detector“ prognostic markers for clear cell renal cell cancer. <i>Nucleic Acids Research</i> , 2016, 44, e1-e1.	6.5	43
99	Personalised cancer care: promises and challenges of targeted therapy. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 98-105.	1.1	13
100	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016, 130, 95-190.	1.1	160
101	Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 122.e1-122.e7.	0.8	23
102	Kidney and Ureteral Carcinoma. , 2016, , 1139-1159.e5.		0
103	TOP2A , HELLS , ATAD2 , and TET3 Are Novel Prognostic Markers in Renal Cell Carcinoma. <i>Urology</i> , 2017, 102, 265.e1-265.e7.	0.5	42
104	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. <i>Oncologist</i> , 2017, 22, 286-292.	1.9	54
105	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. <i>Nature Communications</i> , 2017, 8, 15165.	5.8	61
106	Peroxisome proliferator“activated receptor gamma (PPAR ^γ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target. <i>EMBO Molecular Medicine</i> , 2017, 9, 508-530.	3.3	11
107	Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. <i>European Urology</i> , 2017, 71, 979-985.	0.9	52
108	Heterogeneity in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 507-515.	0.8	88
109	Expression of lactate dehydrogenase C correlates with poor prognosis in renal cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831769596.	0.8	27
110	Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes. <i>Annals of Oncology</i> , 2017, 28, 604-610.	0.6	70
111	Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. <i>Scientific Reports</i> , 2017, 7, 7342.	1.6	46
112	Translational utility of a hierarchical classification strategy in biomolecular data analytics. <i>Scientific Reports</i> , 2017, 7, 14981.	1.6	7

#	ARTICLE	IF	CITATIONS
113	Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?. <i>Cancer</i> , 2017, 123, 200-209.	2.0	30
114	Identification and validation of an eight-gene expression signature for predicting high Fuhrman grade renal cell carcinoma. <i>International Journal of Cancer</i> , 2017, 140, 1199-1208.	2.3	29
115	Molecular Heterogeneity of Renal Cell Carcinoma. , 2017, , 1-8.		0
116	The Emerging Genetic Landscape in Renal Cell Carcinoma. , 2017, , 381-389.		0
117	Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice. <i>Kidney Cancer</i> , 2017, 1, 3-13.	0.2	40
118	Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma. <i>Journal of Cancer</i> , 2017, 8, 2010-2017.	1.2	10
119	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. <i>European Urology</i> , 2018, 74, 474-480.	0.9	72
120	MECHANISMS IN ENDOCRINOLOGY: Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects?. <i>European Journal of Endocrinology</i> , 2018, 178, R155-R181.	1.9	52
121	A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. <i>Biostatistics</i> , 2018, 19, 71-86.	0.9	158
122	Clinical and Molecular Characteristics and Burden of Kidney Cancer Among Hispanics and Native Americans: Steps Toward Precision Medicine. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e535-e541.	0.9	14
123	Clear cell carcinomas of the ovary and kidney: clarity through genomics. <i>Journal of Pathology</i> , 2018, 244, 550-564.	2.1	41
124	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 467-471.	1.0	6
125	Prognostic factors and prognostic models for renal cell carcinoma: a literature review. <i>World Journal of Urology</i> , 2018, 36, 1943-1952.	1.2	162
126	Adjuvant therapy for advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 663-671.	1.1	17
129	Molecular classification of Crohn's disease reveals two clinically relevant subtypes. <i>Gut</i> , 2018, 67, 36-42.	6.1	89
130	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , 2018, 52, 216-227.	4.3	14
131	Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. <i>Acta Oncologica</i> , 2018, 57, 498-508.	0.8	41
132	Personalized Management of Advanced Kidney Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 330-341.	1.8	25

#	ARTICLE	IF	CITATIONS
133	Kidney Cancer: Diagnosis and Treatment. , 2018, , 325-325.		0
134	Whole-transcriptome sequencing identified gene expression signatures associated with aggressive clear cell renal cell carcinoma. <i>Genes and Cancer</i> , 2018, 9, 247-256.	0.6	12
135	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 456.	1.3	40
136	Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC). <i>Kidney Cancer</i> , 2018, 2, 23-29.	0.2	23
137	Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma. <i>Clinical Radiology</i> , 2018, 73, 782-791.	0.5	31
138	Levels of 4EBP1/eIF4E Activation in Renal Cell Carcinoma Could Differentially Predict Its Early and Late Recurrence. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1029-e1058.	0.9	8
139	Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. <i>BMC Medicine</i> , 2018, 16, 108.	2.3	11
140	Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 756-763.	0.9	144
141	The expression analysis of NGAL and NGALR in clear cell renal cell carcinoma. <i>Gene</i> , 2018, 676, 269-278.	1.0	9
142	Recent advances in the theory and practice of Logical Analysis of Data. <i>European Journal of Operational Research</i> , 2019, 275, 1-15.	3.5	30
143	The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. <i>Nature Reviews Urology</i> , 2019, 16, 539-552.	1.9	357
144	Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. <i>Molecular Cancer Research</i> , 2019, 17, 1605-1612.	1.5	21
145	Adjuvant therapy in renal cell carcinoma. <i>Cancer</i> , 2019, 125, 2935-2944.	2.0	47
146	Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 126-132.	0.8	7
147	Patterns of gene expression characterize T1 and T3 clear cell renal cell carcinoma subtypes. <i>PLoS ONE</i> , 2019, 14, e0216793.	1.1	5
148	Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2019, 3, 31-40.	0.2	2
149	Towards individualized therapy for metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 621-633.	12.5	148
150	Clonal architectures predict clinical outcome in clear cell renal cell carcinoma. <i>Nature Communications</i> , 2019, 10, 1245.	5.8	44

#	ARTICLE	IF	CITATIONS
151	The adjuvant treatment of kidney cancer: a multidisciplinary outlook. <i>Nature Reviews Nephrology</i> , 2019, 15, 423-433.	4.1	68
152	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). <i>Scandinavian Journal of Urology</i> , 2019, 53, 14-20.	0.6	15
153	VNN3 is a potential novel biomarker for predicting prognosis in clear cell renal cell carcinoma. <i>Animal Cells and Systems</i> , 2019, 23, 112-117.	0.8	9
154	Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1400.	1.3	39
155	Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 7.e1-7.e8.	0.8	8
156	Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. <i>Cancers</i> , 2020, 12, 99.	1.7	23
157	Transcriptomic characterization and innovative molecular classification of clear cell renal cell carcinoma in the Chinese population. <i>Cancer Cell International</i> , 2020, 20, 461.	1.8	10
158	LAGE3 correlates with tumorigenic immune infiltrates in the clear cell renal cell carcinoma microenvironment. <i>International Immunopharmacology</i> , 2020, 87, 106793.	1.7	15
159	Patient Stratification of Clear Cell Renal Cell Carcinoma Using the Global Transcription Factor Activity Landscape Derived From RNA-Seq Data. <i>Frontiers in Oncology</i> , 2020, 10, 526577.	1.3	7
160	The immunology of renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 721-735.	4.1	229
161	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	7.7	262
162	The Evolution of Angiogenic and Inflamed Tumors: The Renal Cancer Paradigm. <i>Cancer Cell</i> , 2020, 38, 771-773.	7.7	23
163	8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. <i>BMC Urology</i> , 2020, 20, 173.	0.6	1
164	Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1199-1210.	1.1	4
165	The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. <i>Kidney Cancer</i> , 2020, 4, 121-129.	0.2	2
166	Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1594.	1.0	49
167	Genomic profiling in renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 435-451.	4.1	99
168	Differential expression analysis of clear cell renal cell carcinomas in The Cancer Genome Atlas distinguishes an aggressive subset enriched with chromosomes 7 and 12 gains. <i>Histopathology</i> , 2020, 76, 950-958.	1.6	1

#	ARTICLE	IF	CITATIONS
169	Pro-Angiogenic and Pro-Inflammatory Regulation by lncRNA MCM3AP-AS1-Mediated Upregulation of DPP4 in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 705.	1.3	12
171	Classification of clear cell renal cell carcinoma based on PKM alternative splicing. <i>Heliyon</i> , 2020, 6, e03440.	1.4	9
172	Development and validation of a robust multigene signature as an aid to predict early relapse in stage III clear cell and papillary renal cell cancer. <i>Journal of Cancer</i> , 2020, 11, 997-1007.	1.2	9
173	Transcriptomics in Toxicogenomics, Part III: Data Modelling for Risk Assessment. <i>Nanomaterials</i> , 2020, 10, 708.	1.9	38
174	Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients. , 2020, 8, e000447.		35
175	Development and validation of an individualized DNA repair-related gene signature in localized clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1203-1210.	1.2	2
176	Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. <i>Nature Reviews Nephrology</i> , 2021, 17, 245-261.	4.1	278
177	Genetic analysis of primary renal cell carcinoma to determine treatment approaches. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 107-115.	0.4	1
178	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 261-268.	1.3	8
179	Reclassification of Kidney Clear Cell Carcinoma Based on Immune Cell Gene-Related DNA CpG Pairs. <i>Biomedicines</i> , 2021, 9, 215.	1.4	1
181	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1475.	1.7	10
182	Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma. <i>Aging</i> , 2021, 13, 9960-9975.	1.4	19
183	Multiomic Analysis of Cereblon Expression and Its Prognostic Value in Kidney Renal Clear Cell Carcinoma, Lung Adenocarcinoma, and Skin Cutaneous Melanoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 263.	1.1	3
184	Efficient feature selection for logical analysis of large-scale multi-class datasets. <i>Journal of Combinatorial Optimization</i> , 2021, 42, 1-23.	0.8	3
185	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 643065.	1.3	26
186	Quantitative Proteomics Identifies Secreted Diagnostic Biomarkers as well as Tumor-Dependent Prognostic Targets for Clear Cell Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2022, 19, 1322-1337.	1.5	10
187	Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2021, 149, 1448-1454.	2.3	5
188	Identification of subtype specific biomarkers of clear cell renal cell carcinoma using random forest and greedy algorithm. <i>BioSystems</i> , 2021, 204, 104372.	0.9	5

#	ARTICLE	IF	CITATIONS
189	Expression of AOX1 Predicts Prognosis of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 683173.	1.1	5
190	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e382-e394.	0.9	9
191	Integration of <scp>NRP1</scp>, <scp>RGS5,</scp> and <scp>FOXM1</scp> expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 590-603.	1.3	6
192	Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning. <i>IScience</i> , 2021, 24, 102722.	1.9	8
193	Development of a four-gene prognostic model for clear cell renal cell carcinoma based on transcriptome analysis. <i>Genomics</i> , 2021, 113, 1816-1827.	1.3	12
194	On Pareto-Optimal Boolean Logical Patterns for Numerical Data. <i>Applied Mathematics and Computation</i> , 2021, 403, 126153.	1.4	6
195	Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. <i>Cancers</i> , 2021, 13, 4006.	1.7	18
196	Radiology- and gene-based risk stratification in small renal cell carcinoma: A preliminary study. <i>PLoS ONE</i> , 2021, 16, e0256471.	1.1	0
197	The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors. <i>Diagnostics</i> , 2021, 11, 206.	1.3	15
198	Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 375.	1.7	9
199	Logical Analysis of Data: Theory, Methodology and Applications. <i>Intelligent Systems Reference Library</i> , 2013, , 147-192.	1.0	14
201	Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. <i>JCI Insight</i> , 2016, 1, e86051.	2.3	39
202	Differential Expression of Prognostic Proteomic Markers in Primary Tumour, Venous Tumour Thrombus and Metastatic Renal Cell Cancer Tissue and Correlation with Patient Outcome. <i>PLoS ONE</i> , 2013, 8, e60483.	1.1	30
203	Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression. <i>PLoS ONE</i> , 2015, 10, e0103258.	1.1	21
204	Identification of Potential Serum Proteomic Biomarkers for Clear Cell Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e111364.	1.1	27
205	Expression of Ror2 Mediates Invasive Phenotypes in Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e116101.	1.1	20
206	Potential Links Between YB-1 and Fatty Acid Synthesis in Clear Cell Renal Carcinoma. <i>Medical Research Archives</i> , 2020, 8, .	0.1	3
207	An eleven metabolic gene signature-based prognostic model for clear cell renal cell carcinoma. <i>Ageing</i> , 2020, 12, 23165-23186.	1.4	12

#	ARTICLE	IF	CITATIONS
208	Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models. <i>Oncotarget</i> , 2017, 8, 49839-49850.	0.8	24
209	A miRNA-based classification of renal cell carcinoma subtypes by PCR and <i>in situ</i> hybridization. <i>Oncotarget</i> , 2018, 9, 2092-2104.	0.8	22
210	Impact of eIF4E phosphorylation at Ser209 via MNK2a on tumour recurrence after curative surgery in localized clear cell renal cell carcinoma. <i>Oncotarget</i> , 2019, 10, 4053-4068.	0.8	2
211	Combination drug regimens for metastatic clear cell renal cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2020, 11, 541-562.	0.9	19
212	Leukotriene B4 receptor 2 correlates with prognosis and immune infiltration in clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2022, 40, 232-244.	1.2	5
213	Metastasectomy in kidney cancer: current indications and treatment approaches. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 266-275.	0.5	4
214	Molecular Portrait of Clear Cell Renal Cell Carcinoma: An Integrative Analysis of Gene Expression and Genomic Copy Number Profiling. , 0, , .		0
215	Kidney Cancer Genomics: Paving the Road to a New Paradigm of Personalized Medicine. , 2013, , 185-217.		0
217	Microarrays and Renal Cell Cancer Biomarkers. , 2014, , 1-23.		0
218	Cancer of the Kidney. , 2014, , 1416-1444.e5.		1
220	Biomarkers for Renal Cell Carcinoma. , 2015, , 59-82.		0
221	Molecular subtypes and prognosis in RCC. <i>Aging</i> , 2015, 7, 219-220.	1.4	0
223	Molecular Heterogeneity of Renal Cell Carcinoma. , 2019, , 529-536.		0
224	Molecular Biology and Genetics of Renal Cell Carcinoma. , 2020, , 19-33.		0
226	KDM6B induces epithelial-mesenchymal transition and enhances clear cell renal cell carcinoma metastasis through the activation of SLUG. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 6334-44.	0.5	23
228	Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2019, 17, 94-104.	0.1	0
229	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. <i>Cells</i> , 2021, 10, 3231.	1.8	18
230	Mutation Profile Variability in the Primary Tumor and Multiple Pulmonary Metastases of Clear Cell Renal Cell Carcinoma. A Review of the Literature and Analysis of Four Metastatic Cases. <i>Cancers</i> , 2021, 13, 5906.	1.7	2

#	ARTICLE	IF	CITATIONS
231	A renal cell carcinoma tumorgraft platform to advance precision medicine. <i>Cell Reports</i> , 2021, 37, 110055.	2.9	16
232	Identification and Validation of a Novel Pyroptosis-Related Gene Signature for Prognosis Prediction in Soft Tissue Sarcoma. <i>Frontiers in Genetics</i> , 2021, 12, 773373.	1.1	7
233	Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 785410.	1.8	12
234	Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samples. <i>Frontiers of Medicine</i> , 2022, 16, 596-609.	1.5	11
235	Graph, clique and facet of boolean logical polytope. <i>Journal of Global Optimization</i> , 2022, 82, 1015.	1.1	1
236	Liquid biopsy as a new tool for diagnosis, monitoring, and personalized medicine in urogenital cancers. , 2022, , 31-43.		0
237	The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomicsâ€™ Definition, Current Advances, and Future Directions. <i>Cancers</i> , 2022, 14, 793.	1.7	11
238	Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach. <i>EBioMedicine</i> , 2022, 78, 103963.	2.7	11
239	AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease. <i>Cancer Cell International</i> , 2021, 21, 690.	1.8	7
240	Unsupervised Algorithms for Microarray Sample Stratification. <i>Methods in Molecular Biology</i> , 2022, 2401, 121-146.	0.4	3
241	Systems Biology Approaches to Decipher the Underlying Molecular Mechanisms of Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13213.	1.8	3
244	Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions. <i>Cancers</i> , 2022, 14, 2085.	1.7	7
245	Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 2354.	1.7	4
246	Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2022, 40, 54-57.	0.2	2
247	PBX1, EMCN and ERG are associated with the sub-clusters and the prognosis of VHL mutant clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
248	Identification and Verification of Immune Subtype-Related lncRNAs in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
249	Adjuvant therapy in renal cell carcinoma: Ready, steady, should we go?. <i>Bulletin Du Cancer</i> , 2022, , .	0.6	0
250	Identification and Validation of Prognostic Model for Pancreatic Ductal Adenocarcinoma Based on Necroptosis-Related Genes. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	7

#	ARTICLE	IF	CITATIONS
251	Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer. <i>Cancer Research Communications</i> , 2022, 2, 894-903.	0.7	0
252	Characterizing the molecular heterogeneity of clear cell renal cell carcinoma subgroups classified by miRNA expression profile. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
254	The expanding role of BAP1 in clear cell renal cell carcinoma. <i>Human Pathology</i> , 2023, 133, 22-31.	1.1	6
255	Identification of key genes of the ccRCC subtype with poor prognosis. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
256	SNPs and Personalized Medicine: Scrutinizing Pathogenic Synonymous Mutations for Precision Oncology. , 2022, , 185-195.		0
257	Identification and Validation of Two Heterogeneous Molecular Subtypes and a Prognosis Predictive Model for Hepatocellular Carcinoma Based on Pyroptosis. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-19.	1.9	5
258	Identification of ACSL4 as a biomarker and contributor of ferroptosis in clear cell renal cell carcinoma. <i>Translational Cancer Research</i> , 2022, 11, 2688-2699.	0.4	7
259	The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
260	Quantitative Phosphoproteomics Analysis Uncovers PAK2- and CDK1-Mediated Malignant Signaling Pathways in Clear Cell Renal Cell Carcinoma. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100417.	2.5	1
261	Deep learning-based predictions of clear and eosinophilic phenotypes in clear cell renal cell carcinoma. <i>Human Pathology</i> , 2023, 131, 68-78.	1.1	4
262	Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma. <i>Biomedicines</i> , 2022, 10, 2953.	1.4	10
263	Current and Future Biomarkers in the Management of Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2023, 50, 151-159.	0.8	2
264	A <i>Listeria</i> -based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2889-2903.	2.0	4
265	Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies. <i>Cancers</i> , 2022, 14, 6167.	1.7	9
266	The Role of Long Noncoding RNA (lncRNAs) Biomarkers in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 643.	1.8	9
267	Genitourinary cancers immune biomarkers: a comprehensive overview. , 2023, , 389-409.		0
268	Molecular differences in renal cell carcinoma between males and females. <i>World Journal of Urology</i> , 2023, 41, 1727-1739.	1.2	1
269	High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0

#	ARTICLE	IF	CITATIONS
270	Differential Activation of NRF2 Signaling Pathway in Renal-Cell Carcinoma Caki Cell Lines. Biomedicines, 2023, 11, 1010.	1.4	0
271	Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. European Urology, 2023, 84, 166-175.	0.9	7
272	Radiogenomic Associations Clear Cell Renal Cell Carcinoma: An Exploratory Study. Oncology, 2023, 101, 375-388.	0.9	1